Back to today’s briefing

Story perspectives

Albertsons Settles Opioid Claims, Posts $481M Loss

4/14/2026

27 3 Full Breakdown

Summary

Story summary

Albertsons Companies announced a $774 million opioid settlement, contributing to a fourth-quarter net loss of $481 million.
The company posted a nearly 8% rise in quarterly net sales, aided by an extra week, as CEO Susan Morris emphasized personalization and technology.
For fiscal 2026, Albertsons expects 0% to 1% sales growth.
The company will raise its dividend by 13% and remodel stores while opening new locations.

History

Historical Context

Purdue Pharma's 2021 bankruptcy and $4.5 billion settlement marked a significant moment in the opioid crisis, which has resulted in over 500,000 deaths since 1999. The recent $774 million settlement by Albertsons Companies reflects ongoing accountability in the retail sector, emphasizing the need for corporate responsibility as the industry navigates public health challenges and consumer trust issues.

1 of 2

Story summary

Albertsons Companies announced a $774 million opioid settlement, contributing to a fourth-quarter net loss of $481 million.
The company posted a nearly 8% rise in quarterly net sales, aided by an extra week, as CEO Susan Morris emphasized personalization and technology.
For fiscal 2026, Albertsons expects 0% to 1% sales growth.
The company will raise its dividend by 13% and remodel stores while opening new locations.

1 / 2